Philadelphia (Ph) chromosome results from the reciprocal translocation t(9;22)(q34.1;q11.2), and is a diagnostic feature for chronic myeloid leukemia (CML). In most cases, the breakpoint in *BCR* occurs in M-bcr region, leading to production of e13a2 and/or e14a2 fusion transcripts. The breakpoints infrequently occur in either m-bcr or μ-bcr, producing e1a2 or long e19a2 fusion transcripts. Several other variant transcripts, such as e8a2, e13a3, e14a3, and e6a2 have also been identified and account for \<1% of CML cases. Late appearing Ph chromosome may be acquired over the course of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) or MDS, representing disease progression and often signifying poor prognosis. In this report we describe a patient with chronic myelomonocytic leukemia (CMML), a subtype of MDS/MPN, which progressed to AML with gain of the rare BCR-ABL1 fusion transcript e6a2 and died shortly of tumor lysis syndrome.

Fig. 1A; larger BCR-ABL1 fusion product is amplified by multiplex PCR, which is confirmed to be e6a2 by Sanger sequencing. B; Sanger sequencing (reverse read) showed the fusion is between BCR exon 6 and ABL1 exon 2 (corresponding forward read is illustrated under the sequence graph).Fig. 1.

This report illustrates an unusual case of CMML which transformed to AML rapidly with emergence of the rare *BCR-ABL1* e6a2 fusion transcript. The possibility CML in blasts crisis was excluded as the CMML biopsy showed dysgranulopoiesis and lacked Ph chromosome and BCR-ABL1 fusion transcript.

Table 1Clinicopathologic features of reported chronic myeloid neoplasm cases harboring e6a2 fusion transcript.Table 1**Case No.Reference (year)Age/SexDiagnosisBCR/ABL Transcript(s)Treatment**[a](#tbl2fna){ref-type="table-fn"}**Response to TKIClinical course/outcomeSurvival**1Hochhaus [@bib3]41/MCML-CPe6a2HU, allo-BMTNAAP after 19 months Death from sepsis 16 days after BMT33 mo.2Dupont [@bib4]50/MCML-CPe6a2ASCT, αIFN+ara-CNANRNR3Schultheis [@bib5]65/MCML-BPe6a2HU, ImatinibReduction of WBC after 30 daysDeath from pneumonia42 d4Colla [@bib2]76/MCML-CPe6a2HU, αIFNNARelapsed and death from cerebral ictus64 d5Popovici [@bib6]67/MCML-CPe6a2ImatinibComplete hematologic and cytogenetic responseHematologic remissionAlive at 18 mo.6Roti [@bib10]37/MCML-CPe6a2, e1a2ImatinibPartial molecular responseDisease stabilized on imatinibAlive at 21 mo.7Schnittger [@bib1]48/MCML-CPe6a2Imatinib, HU, dasatinibImatinib: disease progression with clonal evolution and resistence mutationsDeath from blast crisis10 mo.Dasatinib: Initial hematologic and cytogenetic remission followed by blast crisis and new resistance mutation8Vefring [@bib7]42/MCML-APe6a2Imatinib, ASCT, dasatinibImatinib: persistent diseaseDeveloped myeloid sarcoma (CML-BP) after ASCT45 mo.Dasatinib: effective on subsequent myeloid sarcomaDeath from hematemesis9Vefring [@bib7]48/MCML-CPe6a2Imatinib, CDA, αIFN, ASCTDisease progressionHematologic remission after ASCTAlive at 62 mo.10Langabeer [@bib8]36/MCML-CPe6a2, e1a2Imatinib, nilotinib, ASCTImatinib: progression to AP with clonal evolutionComplete molecular remissionAlive at 28 mo.Nilotinib: complete cytogenetic remission11Hayette [@bib9]64/FCMMLe6a2 (acquired)ImatinibReduction of BCR/ABL transcript after 3 monthsNRAlive at 3 mo.12Present case58/MCMMLe6a2 (acquired)Induction chemotherapy, dasatinib, nilotinibDasatinib: received only 3 doses due to pneumonitisDisease progression to AML after one month15 mo.Nilotinib: disease progression despite drastic reduction of Ph+ cloneDeath due to rapid disease progression and tumor lysis syndrome[^1]

CML with *BCR-ABL1* e6a2 fusion transcript appears to be associated with more aggressive clinical features, including accelerated/blastic phase on presentation [@bib5], [@bib7], rapid disease progression [@bib1], [@bib3], [@bib8], and imatinib treatment failure [@bib1], [@bib7], [@bib8]. Their response to TKI treatment is variable ([Table 1](#t0005){ref-type="table"}). Briefly, 3 of 7 patients who received a TKI (\#5, \#6, \#10) responded to imatinib, nilotinib, or dasatinib; with disease stabilization or hematologic/molecular remission. Three patients (\#7--9) showed persistent/progressive disease, while one died early from infection (\#3). The other reported CMML case (\#11) showed molecular response to imatinib after 3 months, although long term followup is not available. Our patient is unique since although his Ph+ clone drastically diminished in response to nilotinib (95% to 3.4%), his blast burden remained high (80%) with dominance of the Ph negative clone. Although it is tempting to speculate that the Ph negative clone may have been selected from suppression of the Ph+ clone by nilotinib, the patient's rapidly progressive disease may be due to an inherently aggressive biological behavior of his antecedent CMML and unrelated to TKI therapy, a notion that appears to be supported by the presence of RUNX1 and TP53 mutations in the CMML specimen.

It was hypothesized that shorter BCR-ABL transcripts are associated with a more aggressive clinical course due to lack of important regulatory bcr sequences within the fusion proteins [@bib2]. Specifically in e6a2 transcript, the breakpoint in bcr intron 6 may result in partial loss of GEF/dbl-like domain that mediates interaction with several Ras-like G proteins involved in cell proliferation and signal transduction, which leads to enhanced tyrosine kinase activity of the BCR-ABL1 fusion protein.

In summary, our case illustrates the importance of combining conventional karyotype/FISH and appropriate molecular studies to detect rare BCR-ABL fusion transcripts such as e6a2. As a late appearing secondary Ph chromosome is usually considered a poor prognostic factor in hematopoietic malignancies, individualized therapeutic strategies such as newer TKIs and allogeneic stem cell transplantation may be warranted.

[^1]: Listed temporally. M, male; F, female; CML, chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase; BP, blast phase; AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; HU, hydroxyurea; allo, allogenic; BMT, bone marrow transplant; ASCT, allogenic stem cell transplant; SCT, stem cell transplant; αIFN, alpha interferon; ara-C, cytarabine; CDA, chlorodeoxyadenosine; TKI, tyrosine kinase inhibitor; mo., months; d, days; NR, not.
